ZYME vs. BHVN, VRNA, ACLX, CRNX, APLS, PTCT, RNA, RYTM, IMVT, and ACAD
Should you be buying Zymeworks stock or one of its competitors? The main competitors of Zymeworks include Biohaven (BHVN), Verona Pharma (VRNA), Arcellx (ACLX), Crinetics Pharmaceuticals (CRNX), Apellis Pharmaceuticals (APLS), PTC Therapeutics (PTCT), Avidity Biosciences (RNA), Rhythm Pharmaceuticals (RYTM), Immunovant (IMVT), and ACADIA Pharmaceuticals (ACAD). These companies are all part of the "pharmaceutical products" industry.
Zymeworks vs.
Zymeworks (NYSE:ZYME) and Biohaven (NYSE:BHVN) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, profitability, earnings, media sentiment, institutional ownership, risk, community ranking and analyst recommendations.
In the previous week, Zymeworks had 3 more articles in the media than Biohaven. MarketBeat recorded 10 mentions for Zymeworks and 7 mentions for Biohaven. Zymeworks' average media sentiment score of 1.26 beat Biohaven's score of 0.01 indicating that Zymeworks is being referred to more favorably in the media.
Biohaven received 109 more outperform votes than Zymeworks when rated by MarketBeat users. However, 67.75% of users gave Zymeworks an outperform vote while only 67.17% of users gave Biohaven an outperform vote.
92.9% of Zymeworks shares are held by institutional investors. Comparatively, 88.8% of Biohaven shares are held by institutional investors. 1.9% of Zymeworks shares are held by company insiders. Comparatively, 16.0% of Biohaven shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Zymeworks has a beta of 1.1, suggesting that its stock price is 10% more volatile than the S&P 500. Comparatively, Biohaven has a beta of 1.29, suggesting that its stock price is 29% more volatile than the S&P 500.
Zymeworks has higher revenue and earnings than Biohaven. Zymeworks is trading at a lower price-to-earnings ratio than Biohaven, indicating that it is currently the more affordable of the two stocks.
Biohaven has a net margin of 0.00% compared to Zymeworks' net margin of -182.75%. Zymeworks' return on equity of -23.00% beat Biohaven's return on equity.
Zymeworks currently has a consensus target price of $19.17, suggesting a potential upside of 38.09%. Biohaven has a consensus target price of $63.00, suggesting a potential upside of 67.70%. Given Biohaven's stronger consensus rating and higher possible upside, analysts plainly believe Biohaven is more favorable than Zymeworks.
Summary
Zymeworks beats Biohaven on 9 of the 17 factors compared between the two stocks.
Get Zymeworks News Delivered to You Automatically
Sign up to receive the latest news and ratings for ZYME and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Zymeworks Competitors List
Related Companies and Tools
This page (NYSE:ZYME) was last updated on 1/18/2025 by MarketBeat.com Staff
